The next time you order your next shot of cough syrup, be sure to take a look at this new study that’s revealing just how good Vivera Pharmaceuticals’ inhaler is at combating COVID-19.
Viveras’ inhalers are currently the most popular among cough syrups in the US, and its brand has also taken off among healthcare workers.
And if you haven’t heard of Viverab, you should start.
The study, which was conducted by the U.S. Food and Drug Administration (FDA), is the first to find that Viverabs inhalers contain far less toxins than standard cough syrup.
That means you’re unlikely to inhale harmful levels of toxic metals like lead, cadmium, mercury, arsenic, and other toxins into your lungs, as some people have been experiencing.
The researchers, led by Amit Kumar, associate professor of pharmaceutical engineering at the University of Pittsburgh School of Engineering and Applied Science, also found that Vivenab’s inhalers were 95% effective against COVID in humans, and nearly 100% effective in preventing coronavirus infection in the animals they tested.
The researchers found that the Viveros inhalers had significantly lower levels of toxins than the standard cough syrup.
The study is being published in the journal Antimicrobial Agents and Chemotherapy.
The Viverapay inhalers, developed by Viverax Pharmaceuticals, also had significant advantages over the standard inhalers.
They contained less water than standard syruptes, which makes them more effective for both short and long-term use.
They were also less expensive, at about $40, compared to Viver’s $100 standard inhaler.
The scientists also found Viverash inhalers contained significantly fewer metals than standard versions, which may have a beneficial effect on reducing exposure to the toxins, said Kumar.
And because they contain far fewer toxins, they’re less likely to cause a reaction, which means they are also less likely than standard forms to cause side effects like nausea, headache, and fatigue.
In an email to TechCrunch, ViverA spokesperson explained the company’s motivation for making the inhalers: “The fact that the inhaler contains less toxic metals than the traditional product is because it is made from a pure form of plastic, which has been proven to be highly effective at preventing COVID infection in humans.”
Viverab’s most notable innovation was the addition of a COVID vaccine, which is currently being tested in humans and has been approved by the FDA for use in Europe.
The company said it is also looking into adding more pharmaceuticals to its inhalers line, but declined to say whether the vaccines would be made available to the general public.
The team also found the Vivenas inhalers reduced COVID deaths by over 10% in animals, which can be a good thing for anyone who’s been coughing up the virus.
The biggest drawback to Vivenabs inhaler, though, is that it is extremely difficult to use.
The team found that most patients will have difficulty breathing through a Viverablair inhaler due to the high concentration of COVID toxins.
The inhalers also have a tendency to burn.
They’re not designed to burn a patient, and the researchers said the inhalants aren’t intended for the burning of human tissue, either.
The inhalers can be very difficult to clean, too, and you may have to scrub them with a brush to avoid contaminating your work.
Viveras says the VIVX inhalers have the ability to be worn over the patient’s mouth to mask the respiratory symptoms of COIDS, and it has also tested them in a pet as well.
But that doesn’t mean you should use the inhalators in your home.
Vivers are not approved for use by pets.
The FDA says the inhalable devices are also not meant for use inside of a home or hotel.
Vivena is currently developing a new product line that will be manufactured and sold by a pharmaceutical company that will sell it in the U: Viverad.
VIVx inhalers and Viveraby inhalers will be sold separately in the coming months.